American Heart Journal
Volume 141, Issue 2, Supplement , Pages S15-S21 , February 2001

Pharmacologic management of atrial fibrillation: Current therapeutic strategies

References 

  1. Kannel WB, Abbot RD, Savage DD, et al.  Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018–1022
  2. Wolf PA, Abbott RD, Kannel WB. A major contributor to stroke in the elderly. Arch Int Med. 1987;147:1561–1564
  3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke;: The Framingham Study. Stroke. 1991;22:983–988
  4. BAATAF Investigators . The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med. 1990;323:1505–1511
  5. Stroke Prevention in Atrial Fibrillation Investigators (SPAF) . Stroke Prevention in Atrial Fibrillation Study: final results. Circulation. 1991;84:527–539
  6. The European Atrial Fibrillation Trial Study Group . Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. N Engl J Med. 1995;333:5
  7. Allessie M, Rensma PPL, Lammers WJEP, et al.  The role of refractoriness, conduction velocity and wavelength in initiation of atrial fibrillation in normal dogs. In:  Attuel P,  Coumel P,  Janse MJ editor. The atrium in health and disease. Mount Kisco (NY): : Futura Publishing; 1989;p. 27–41
  8. Wijfells MC, Kirchhof CJHJ, Dorland R, et al.  Atrial fibrillation begets atrial fibrillation. A study in awake chronically instrumented goats. Circulation. 1995;92:1954–1968
  9. Lévy S. Nomenclature of atrial fibrillation or the Tower of Babel. J Cardiovasc Electrophysiol. 1998;9:583–585
  10. Vaughan-Williams EM. A classification of antiarrhythmic action reassessed after a decade of new drugs. J Clin Pharmacol. 1984;24:129–147
  11. Capucci A, Tiziano L, Boriani G, et al.  Effectiveness of loading oral flecainide for converting recent-onset atrial fibrillation to sinus rhythm in patients without organic heart disease or with only systemic hypertension. Am J Cardiol. 1992;70:69–72
  12. Crijns HJGM, van Vijk M, van Gilst WH, et al.  Acute conversion of atrial fibrillation to sinus rhythm: clinical efficacy of flecainide acetate. Comparison of two regimens. Eur Heart J. 1988;9:634–639
  13. Suttorp MJ, Kingma HJ, Jessurun ER, et al.  The value of class 1C antiarrhythmic drugs for acute conversion of paroxysmal atrial fibrillation or flutter to sinus rhythm. J Am Coll Cardiol. 1990;16:1722–1727
  14. Capucci A, Boriani G, Rubino I, et al.  A controlled study on oral propafenone versus digoxin plus quinidine in converting recent onset atrial fibrillation to sinus rhythm. Int J Cardiol. 1994;43:305–311
  15. Boriani G, Biffi M, Capucci A, et al.  Oral propafenone to convert recent-onset atrial fibrillation in patients with and without underlying heart disease. A randomized controlled trial. Ann Intern Med. 1997;126:621–624
  16. Falk RH, Knowlton AA, Bernard SA, et al.  Digoxin for converting recent-onset atrial fibrillation to sinus rhythm. A randomized double-blinded trial. Ann Inter Med. 1987;106:503–506
  17. Jordaens L, Trouerbach J, Calle P, et al.  Conversion of atrial fibrillation to sinus rhythm and rate control by digoxin in comparison to placebo. Eur Heart J. 1997;18:643–648
  18. Donovan KD, Dower BM, Hockings BE, et al.  Flecainide versus amiodarone for recent onset atrial fibrillation. Am J Cardiol. 1995;75:693–697
  19. Galve E, Rius T, Ballester R, et al.  Intravenous amiodarone in the treatment of recent-onset atrial fibrillation. Results of a randomized, controlled trial. J Am Coll Cardiol. 1996;27:1079–1082
  20. Ellenbogen KA, Wood M, Stambler BS, et al.  Conversion of atrial fibrillation and flutter by intravenous ibutilide: a multicenter dose response study. J Am Coll Cardiol. 1996;28:130–136
  21. Falk RH, Pollak A, Singh SN, et al.  Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. J Am Coll Cardiol. 1997;29:385–390
  22. Coumel P, Friocourt P, Múgica J, et al.  Long-term prevention of vagal atrial arrhythmias by atrial pacing at 90/minute: experience with 6 cases. PACE. 1983;6:552–560
  23. Schwartz PJ, Priori SG. Sympathetic nervous system and cardiac arrhythmias. In:  Zipes DP,  Jalife J editor. Cardiac electrophysiology. From cell to bedside. Philadelphia: : WB Saunders; 1990;p. 330–343
  24. The Planning and Steering Committees of the AFFIRM Study for the NHLBI AFFIRM Investigators . Atrial fibrillation follow-up investigation of rhythm management: the AFFIRM study design. Am J Cardiol. 1997;79:1198–1202
  25. Coplen SE, Antman EM, Berlin JA, et al.  Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials. Circulation. 1990;82:1106–1116
  26. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N. Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation. 1990;82:1932–1939
  27. Crijns HJ, Van Gelder IC, Van Gilst WH, et al.  Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol. 1991;68:335–341
  28. Reimold SC, Cantillon CO, Friedman PL, et al.  Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol. 1993;71:558–563
  29. Levy S, Novella P, Ricard PH, et al.  Paroxysmal atrial fibrillation: a need for a classification. J Cardiovasc Electrophysiol. 1995;6:69–74
  30. Anderson JL, Gilbert EM, Alpert BL, et al.  Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. Circulation. 1989;80:1557–1570
  31. Antman EM, Beamer AD, Caytillon C, et al.  Long term oral propafenone therapy for suppression of refractory symptomatic atrial fibrillation and atrial flutter. J Am Coll Cardiol. 1988;12:1005–1011
  32. Pritchett ELC, McCarthy EA, Wilkinson WE. Propafenone treatment of symptomatic paroxysmal supraventricular arrhythmias: a randomized, placebo-controlled, crossover trial in patients tolerating oral therapy. Ann Intern Med. 1991;114:539–544
  33. Flaker GC, Blackshear JL, McBride R, et al.  Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol. 1992;20:527–532
  34. Gosselink ATM, Crijns HJGM, Van Gelder IC, et al.  Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA. 1992;267:3289–3293
  35. Roy D, Talajic M, Dorian P, et al.  Amiodarone to prevent recurrences of atrial fibrillation. N Engl J Med. 2000;342:913–920
  36. Levy S. Amiodarone in atrial fibrillation. Int J Clin Pract. 1998;52:429–431
  37. Feld GH, Chen PS, Nicod P, et al.  Atrial proarrhthymic effects of class 1C antiarrhythmic drugs. Am J Cardiol. 1990;66:378–382
  38. Rikkenberger RL, Prystowsky EN, Heger JJ, et al.  Effects of intravenous and chronic oral verapamil. Circulation. 1980;62:996–1010
  39. Lewis RV, McMurray J, McDevitt DG. Effects of atenolol, verapamil, and xamoterol on heart rate and exercise tolerance in digitalized patients with chronic atrial fibrillation. J Cardiovasc Pharmacol. 1989;13:1–6
  40. Rawles M, Metcalfe MJ, Jennings K. Time of occurrence, duration, and ventricular rate of paroxysmal atrial fibrillation: the effect of digoxin. Br Heart J. 1990;63:225–227
  41. Lévy S, Breithardt G, Campbell RWF, et al.  Atrial fibrillation: current knowledge and recommendations for management. Eur Heart J. 1998;19:1294–1320

☆ Reprint requests: Samuel Lévy, MD, Division of Cardiology, Hôpital Nord, Marseille, 13015 France. E-mail: slevy@ap-hm.fr

PII: S0002-8703(01)70039-7

American Heart Journal
Volume 141, Issue 2, Supplement , Pages S15-S21 , February 2001

Article Tools